Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (11): 1065-1069.doi: 10.35541/cjd.20210232

• Reviews • Previous Articles     Next Articles

Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases: from basic research to clinical application

You Ruixuan, Zeng Zhuotong, Qiu Xiangning, Xiao Rong   

  1. Department of Dermatology and Venereology, The Second Xiangya Hospital of Central South University, Changsha 410011, China
  • Received:2021-03-22 Revised:2021-11-03 Online:2023-11-15 Published:2023-11-03
  • Contact: Xiao Rong
  • Supported by:
    National Natural Science Foundation of China(82073449)

Abstract: 【Abstract】 Interleukin-17 (IL-17) has been proved to be closely associated with the pathogenesis of various inflammatory skin diseases. Its main source is Th17 cells, whose differentiation is evoked by interleukin-23 (IL-23). Therefore, the IL-23/Th17 axis is an emerging target for the treatment of inflammatory skin diseases. IL-17 antagonists, IL-23 antagonists and IL-12/23 antagonists have shown satisfactory efficacy and safety in the treatment of psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris and SAPHO syndrome in latest clinical trials. Accordingly, this review mainly summarizes progress in molecular signaling pathways in and pathophysiological basis of the IL-23/Th17 axis in the occurrence of inflammatory skin diseases, as well as clinical application of different biological agents targeting this axis.

Key words: Biological agents, Interleukin-17, Interleukin-23, Psoriasis, Dermatitis, atopic, Inflammatory skin diseases